1. Cancer specific up-regulated lactate genes associated with immunotherapy resistance in a pan-cancer analysis
- Author
-
Shuiting Fu, Jiachen Xu, Chunming Wang, Cheng Zhang, Chengcheng Li, Wenchuan Xie, Guoqiang Wang, Xin Zhu, Yuyan Xu, Yaohong Wen, Jingyuan Pei, Jun Yang, Mingyang Tang, Hongkun Tan, Shangli Cai, Lei Cai, and Mingxin Pan
- Subjects
Lactate ,Immunosuppression ,Immune checkpoint inhibitor ,Cancer intrinsic feature ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Background: Although the lactate pathway has been reported to lead to immune escape through the inhibition of effector T cells, the cancer-intrinsic lactate signature has not been identified, and the immunotherapeutic efficacy and potential mechanism of the lactate signature are still unclear. Methods: We defined a pan-cancer up-lactate score by comparing malignant tissues and normal tissues in the TCGA cohort. The immunotherapeutic efficacy was evaluated in non-small cell lung cancer (NSCLC), metastatic renal cancer (mRCC), bladder cancer (BLCA) and melanoma cohorts. The cancer cell-intrinsic mechanism to immune checkpoint inhibitors (ICIs) resistance was measured using single cell sequencing (scRNA-seq) data. Pathway activation was evaluated in the TCGA cohort and CPTAC cohort with transcriptomics and proteomics. The co-occurrence of up-lactate signature and mTOR signaling was determined by spatial transcriptomics of the tissue samples. Immunotherapy resistance and pathway regulation were validated in the in-house NSCLC cohort. Results: Patients with the high up-lactate scores had significantly short overall survival (OS) than those with the low up-lactate scores (p
- Published
- 2024
- Full Text
- View/download PDF